| Price | $4.33 |
| Year Range | $3.17 – $5.34 |
| Market Cap | $180M |
| PE Ratio | 1.05 |
| Industry | Biotechnology |
What Is Oramed Pharmaceuticals’s AI Stock Analysis?
Oramed Pharmaceuticals’s AI stock analysis on AltIndex combines the company’s fundamentals, price technicals and 25+ alternative data signals — like hiring, web traffic, app downloads and online sentiment — into a single AI Score from 0 to 100 and a plain-English Buy, Hold or Sell read. Unlike a traditional analyst rating that updates a few times a year, the AI Score refreshes as new data arrives, so it tracks Oramed Pharmaceuticals’s momentum in near-real time.
Oramed Pharmaceuticals (ORMP) has an AltIndex AI Score of 42/100, currently a Hold signal. The AI Score distills Oramed Pharmaceuticals's fundamentals, price technicals and 25+ alternative data signals into a single 0–100 rating, so a rising score reflects strengthening data across the board and a falling score the opposite.
Oramed Pharmaceuticals’s Full AI Analysis
Keep reading AltIndex’s full AI analysis of Oramed Pharmaceuticals — the fundamental, technical and alternative-data breakdown and the recommendation.
Sign up to read the full analysisWhat’s Driving ORMP’s AI Score?
Fundamentals
Net income for the last quarter was $78M. This is an increase of 104.01% compared to the quarter before it, which is a positive sign of growth. Compared to the same quarter last year, there is an increase of 488.17%, suggesting positive year-over-year growth. Ebitda for the last quarter was $102M. This is an increase of -2,899.31% compared to the quarter before it, which is a positive sign of growth. Compared to the same quarter last year, there is an increase of 671.70%, suggesting positive year-over-year growth. The current P/E ratio is 1.05. This may be considered low, potentially indicating undervaluation and a bullish outlook.
See Oramed Pharmaceuticals’s earnings and insider transactions.
Technicals
Today's stock price is $4.33. This represents a decrease of 9.03% compared to a month ago, which may be concerning in the short-term. Compared to a year ago, there is an increase of 91.59%, suggesting a positive long-term trend. The trend is bearish. The current SMA10 is $4.45, which is lower than the previous SMA10 of $4.48. This suggests a potential downward trend in price movement. The RSI is 47.6, indicating a neutral condition.
See the full technical analysis and price prediction.
Alternative data
Oramed Pharmaceuticals has an estimate of 1,000 visitors to their webpage. The number of visitors is down by -50% in the last couple of months, a worrisome trend as this can indicate a loss in customers.
Explore Oramed Pharmaceuticals’s job postings, web traffic and app downloads.
Sentiment & social
Oramed Pharmaceuticals has 1,600 followers on their Twitter page. The number of followers is down by -0% in the last couple of months, indicating a loss in interest in the company.
Track Oramed Pharmaceuticals’s market sentiment.
Frequently Asked Questions: Oramed Pharmaceuticals AI Stock Analysis
Oramed Pharmaceuticals's AltIndex AI Score is 42/100, currently a Hold signal. The AI Score blends fundamentals, technicals and 25+ alternative data signals into a single rating from 0 to 100.
AltIndex's AI Score model rates Oramed Pharmaceuticals a Hold (42/100). This is a data-driven signal, not investment advice — review the breakdown above and combine it with your own research.
The AI Score is generated from fundamental data (earnings, valuation), technical indicators (price trend and momentum), and alternative data signals such as hiring, web traffic, app downloads and sentiment. AltIndex weighs these into a single 0-100 score; the exact weighting is proprietary.
AltIndex generates a complete written AI analysis of Oramed Pharmaceuticals — company overview, fundamentals, technicals and alternative data, with a recommendation. See the ORMP AI Score or sign up to read the full thesis.
